Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference27 articles.
1. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness;Chen;Health Technol Assess,2006
2. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment;Emery;Rheumatology (Oxford),2012
3. A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm;Tak;Rheumatology (Oxford),2012
4. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients;Du Pan;Ann Rheum Dis,2012
5. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFalpha blocker failure;Kekow;Biologics,2012
Cited by 96 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?;BioDrugs;2023-11-21
2. Inflammation aiguë, inflammation chronique - 4e partie. Pharmacologie inhibitrice des récepteurs de l’IL-6 (IL-6R, sIL-6r et sGP130);Douleurs : Évaluation - Diagnostic - Traitement;2023-10
3. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease;Nature Reviews Rheumatology;2023-05-25
4. Photobiomodulation ameliorates inflammatory parameters in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis;Frontiers in Immunology;2023-03-29
5. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena;Transplantation;2023-01-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3